Latest MAYNE PHARMA (ASX:MYX) News

Mayne Pharma rejects Cosette Pharmaceuticals’ claims of valid termination of their scheme deal, setting the stage for a September court showdown while urging shareholders to back the scheme in June.

Mayne Pharma has dismissed a fresh termination notice from Cosette Pharmaceuticals, reaffirming its commitment to proceed with the upcoming Scheme Meeting on 18 June 2025. The dispute centers on the validity of the Scheme Implementation Deed termination claims.

Mayne Pharma disputes Cosette Pharmaceuticals’ attempt to terminate their acquisition agreement, with a key court hearing postponed to September and a crucial shareholder vote set for June 18.

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ notice attempting to terminate their merger agreement, setting the stage for a potential courtroom showdown over the disputed deal.

Mayne Pharma rebuffs Cosette's claim of a material adverse change in their merger scheme and secures FDA clearance on regulatory concerns, maintaining its commitment to the deal's completion.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ assertion of a Material Adverse Change that could derail their acquisition scheme, insisting the deal process continues as planned.

Mayne Pharma has sent out the Scheme Booklet to shareholders, marking a key step in the proposed acquisition by Cosette. The booklet includes critical details to guide shareholder decisions ahead of the upcoming Scheme Meeting.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.